[go: up one dir, main page]

TR200600945T1 - Terapötik usuller. - Google Patents

Terapötik usuller.

Info

Publication number
TR200600945T1
TR200600945T1 TR2006/00945T TR200600945T TR200600945T1 TR 200600945 T1 TR200600945 T1 TR 200600945T1 TR 2006/00945 T TR2006/00945 T TR 2006/00945T TR 200600945 T TR200600945 T TR 200600945T TR 200600945 T1 TR200600945 T1 TR 200600945T1
Authority
TR
Turkey
Prior art keywords
cholesterol
products
therapeutic methods
binding units
ozonation products
Prior art date
Application number
TR2006/00945T
Other languages
English (en)
Inventor
Wentworth Paul
A. Lerner Richard
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of TR200600945T1 publication Critical patent/TR200600945T1/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/523—Saturated compounds containing a keto group being part of a ring containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/757—Unsaturated compounds containing a keto groups being part of a ring containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
    • C07C59/353—Saturated compounds containing more than one carboxyl group containing keto groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/04—Seven-membered rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Burada açıklandığı gibi kolesterol, aterosklerotik plaklar içinde bulunduğu zaman oksitlenir. Bu reaksiyon sitotoksik kolesterol oksitlenme veya ozonlanma ürünleri meydana getirir. Bu müracaat, kolesterol ozonlanma ürünleri, bu gibi ürünlere karşı yöneltilmiş bağlayıcı birimler, ve bu gibi bağlayıcı birimlerin ve sitotoksinlerin, çeşitli hastalıkları tedavi etmek için bir ilaç üretilmesinde kullanımı ile ilgilidir.
TR2006/00945T 2003-09-05 2004-09-03 Terapötik usuller. TR200600945T1 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50084503P 2003-09-05 2003-09-05
US51794003P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
TR200600945T1 true TR200600945T1 (tr) 2006-10-26

Family

ID=34278722

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2006/00945T TR200600945T1 (tr) 2003-09-05 2004-09-03 Terapötik usuller.

Country Status (9)

Country Link
US (2) US20050085557A1 (tr)
EP (1) EP1670812A2 (tr)
JP (1) JP2007504244A (tr)
AU (1) AU2004270702B2 (tr)
BR (1) BRPI0414093A (tr)
CA (1) CA2537976A1 (tr)
MX (1) MXPA06002441A (tr)
TR (1) TR200600945T1 (tr)
WO (1) WO2005023830A2 (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8177762B2 (en) 1998-12-07 2012-05-15 C. R. Bard, Inc. Septum including at least one identifiable feature, access ports including same, and related methods
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
EP1670812A2 (en) * 2003-09-05 2006-06-21 The Scripps Research Institute Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases
BRPI0414154A (pt) * 2003-09-05 2006-10-31 Scripps Resarch Inst detecção de produtos de ozonização do colesterol
US9474888B2 (en) 2005-03-04 2016-10-25 C. R. Bard, Inc. Implantable access port including a sandwiched radiopaque insert
JP5484674B2 (ja) 2005-03-04 2014-05-07 シー・アール・バード・インコーポレーテッド アクセスポートおよびその識別方法
US7947022B2 (en) 2005-03-04 2011-05-24 C. R. Bard, Inc. Access port identification systems and methods
US8029482B2 (en) 2005-03-04 2011-10-04 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
EP2324880B1 (en) 2005-04-27 2014-12-24 C.R. Bard, Inc. Infusion apparatuses provided with septum
WO2006116613A1 (en) 2005-04-27 2006-11-02 C.R. Bard, Inc. Infusion apparatuses
US10307581B2 (en) 2005-04-27 2019-06-04 C. R. Bard, Inc. Reinforced septum for an implantable medical device
RU2008105806A (ru) * 2005-08-15 2009-09-27 Зе Скрипс Ресеч Инститьют (Us) Способы выявления терапевтических агентов
US7722665B2 (en) 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
US8021324B2 (en) 2007-07-19 2011-09-20 Medical Components, Inc. Venous access port assembly with X-ray discernable indicia
US9642986B2 (en) 2006-11-08 2017-05-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US9265912B2 (en) 2006-11-08 2016-02-23 C. R. Bard, Inc. Indicia informative of characteristics of insertable medical devices
EP3269417B1 (en) 2007-06-20 2025-09-24 Medical Components, Inc. Implantable access port with molded and/or radiopaque indicia
WO2009012395A1 (en) 2007-07-19 2009-01-22 Innovative Medical Devices, Llc Venous access port assembly with x-ray discernable indicia
US9579496B2 (en) 2007-11-07 2017-02-28 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
EP2346553B1 (en) 2008-10-31 2022-01-19 C.R. Bard, Inc. Systems and methods for identifying an access port
US11890443B2 (en) 2008-11-13 2024-02-06 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US8932271B2 (en) 2008-11-13 2015-01-13 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
WO2010147677A2 (en) * 2009-06-19 2010-12-23 Acquisci, Inc. Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
US8715244B2 (en) 2009-07-07 2014-05-06 C. R. Bard, Inc. Extensible internal bolster for a medical device
WO2011062750A1 (en) 2009-11-17 2011-05-26 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
USD676955S1 (en) 2010-12-30 2013-02-26 C. R. Bard, Inc. Implantable access port
USD682416S1 (en) 2010-12-30 2013-05-14 C. R. Bard, Inc. Implantable access port
JP6397695B2 (ja) * 2014-08-25 2018-09-26 学校法人自治医科大学 抗ピロリ菌剤
MX2018003258A (es) * 2015-09-20 2019-02-07 Air Cross Inc Ozonolisis para la activacion de compuestos y degradacion de ozono.
CN112479416A (zh) * 2020-10-28 2021-03-12 惠州市东江环保技术有限公司 一种无机废水处理工艺

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US6025477A (en) 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
JP2002504225A (ja) * 1995-12-05 2002-02-05 エントレメッド インコーポレイテッド 抗コレステロール抗体を用いるアテローム性動脈硬化の診断および治療方法
EP0985039B1 (en) * 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
EP1670812A2 (en) * 2003-09-05 2006-06-21 The Scripps Research Institute Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases
BRPI0414154A (pt) * 2003-09-05 2006-10-31 Scripps Resarch Inst detecção de produtos de ozonização do colesterol

Also Published As

Publication number Publication date
US20050085557A1 (en) 2005-04-21
JP2007504244A (ja) 2007-03-01
BRPI0414093A (pt) 2006-10-31
MXPA06002441A (es) 2006-06-20
WO2005023830A3 (en) 2005-08-18
EP1670812A2 (en) 2006-06-21
AU2004270702A1 (en) 2005-03-17
CA2537976A1 (en) 2005-03-17
AU2004270702B2 (en) 2009-08-06
US20060217359A1 (en) 2006-09-28
WO2005023830A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
TR200600945T1 (tr) Terapötik usuller.
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO993393D0 (no) Fotokjemoterapeutiske blandinger
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
WO2009149369A3 (en) Acne treatment compositions comprising nanosilver and uses
MX2008002190A (es) Metodos para identificar agentes terapeuticos.
AU2002351196A1 (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
IL169897A0 (en) Sustituted heterocycles
GB2442915B (en) Perylenequinone derivatives and uses thereof
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
MXPA06000464A (es) Uso de biotina o un derivado de biotina para aclarar la piel y tratar manchas por envejecimiento.
WO2007130501A3 (en) Combination therapy for treatment of cancer
BR0009211A (pt) Derivados de resorcinol
DK1558620T3 (da) Rutheniumkomplekser med anticancervirkning
WO2006053788A3 (en) Alterations in seborrheic keratoses and their applications
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
TW200504051A (en) Novel acridine derivatives and their use as medicaments
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
ATE405276T1 (de) Pharmazeutische gel-zusammensetzung
WO2008008513A3 (en) Combination treatments
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders